Stockscreener 앱 받기
18.57
0.87%
0.12
전일 마감가:
$18.45
열려 있는:
$18.65
하루 거래량:
149.75K
Relative Volume:
0.17
시가총액:
$2.45B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-8.6372
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+3.62%
1개월 성능:
+9.41%
6개월 성능:
-28.04%
1년 성능:
-4.76%
1일 변동 폭
$18.52
$18.97
1주일 범위
$17.63
$18.97
52주 변동 폭
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
18.57 | 2.45B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
528.53 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.04 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.07 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.14 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug By Investing.com - Investing.com South Africa
Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus
How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com
Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India
NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com
California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel - Insider Monkey
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Frazier Lifesciences Acquisition : NewAmsterdam Pharma R&D Day 2025 - MarketScreener
NewAmsterdam Pharma Schedules R&D Day for June 2025 - TipRanks
Brokers Set Expectations for NAMS FY2026 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus - Defense World
Kalkine: NewAmsterdam Pharma Progress in Nasdaq Index Spotlight Event - Kalkine Media
(NAMSW) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14% - simplywall.st
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14% - Yahoo Finance
Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target - marketscreener.com
Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Pos - GuruFocus
Stifel initiates NewAmsterdam stock with Buy rating, $44 target - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data fr - GuruFocus
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib - Benzinga
NewAmsterdam Says Obicetrapib Shows 'Significant' Reduction in Alzheimer's Biomarker; Shares Rise - marketscreener.com
NewAmsterdam reports Alzheimer’s biomarker reduction - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data from Key Trial | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Reveals Positive Topline Data From BROADWAY Clinical Trial - Nasdaq
NewAmsterdam reports Alzheimer’s biomarker reduction By Investing.com - Investing.com India
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial - GlobeNewswire
NewAmsterdam Pharma Company N.V. Announces Positive Topline Alzheimer's Disease Data from Br Broadway Clinical Trial - marketscreener.com
Bank of America Corp DE Grows Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Approves Key Proposals at AGM - TipRanks
NewAmsterdam Pharma to Host R&D Day on June 11, 2025 - GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Cantor Fitzgerald - Defense World
NewAmsterdam Pharma R&D Day: Key Pipeline Updates Coming for Revolutionary Cardiovascular Treatments - Stock Titan
NewAmsterdam Pharma (NAMS) versus Its Rivals Head-To-Head Review - Defense World
NewAmsterdam Pharma (NAMS) Receives Overweight Rating from Canto - GuruFocus
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock By Investing.com - Investing.com India
Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com Canada
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Newamsterdam Pharma Company Nv 주식 (NAMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kling Douglas F | Chief Operating Officer |
Jun 16 '25 |
Sale |
19.29 |
100,000 |
1,929,141 |
44,000 |
| Topper James N | Director |
Jun 16 '25 |
Buy |
19.50 |
8,584 |
167,381 |
3,022,153 |
1.37%
0.65%
자본화:
|
볼륨(24시간):